Skip Navigation
CIBMTR Logo Sharing knowledge. Sharing Hope.

Home  /   Studies  /   Observational Research  /   Study Lists  /   Regimen-Related Toxicity and Supportive Care Working Committee
  • Print
  • Share

Regimen-Related Toxicity and Supportive Care Working Committee Studies

The Regimen-Related Toxicity and Supportive Care Working Committee provides scientific oversight for studies related to preparative regimens, prevention and treatment of early non-GVHD toxicities and supportive care in the early post-transplant period.

Learn more about the studies conducted through the Regimen-Related Toxicity and Supportive Care Working Committee using the links below.

Studies In Progress

NumberTitleStatus
D98-70 Comparative analysis of busulfan (Bu) and cyclosphosphamide (Cy) versus cyclosphosphamide and total body irradiation (TBI) in full intensity unrelated donor hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplasia (MDS) Submitted
RT05-03 Second unrelated donor transplantation as a rescue strategy for 122 patients with primary nonengraftment: Results from the CIBMTR. Submitted

Publication(s)
SC03-01/R02-26 Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. Submitted
RT05-02 Lower body mass index (BMI) prior to transplantation as an indicator of increased risk for morbidity and mortality during the first 100 days after the transplantation process. Manuscript Preparation

Abstract(s)
RT06-01s Evaluation of transforming growth factor beta 1 (TGF-B1) promoter and signal peptide polymorphisms as risk factors for renal dysfunction in hematopoietic cell transplant (HCT) patients treated with cyclosporine A. Manuscript Preparation
RT06-02 A longitudinal study of transplant-related mortality (TRM) to determine how innovations in clinical care over the past two decades have affected the safety of myeloablative allogeneic hematopoietic stem cell transplantation (HCT). Manuscript Preparation

Abstract(s)

Planned Studies

NumberTitleStatus
RT08-01 End stage renal disease (ESRD) in hematopoietic stem cell transplantation (HCT). Data File Preparation
RT08-02 Effect of prior splenectomy on myeloid engraftment after ablative allogeneic hematopoietic stem cell transplantation (HCT). Data File Preparation
RT07-01 Interaction between co-morbidities and aging and their combined impact on hematopoietic cell transplantation (HCT) outcomes. Supplemental Forms/Data Collection
RT05-01 Role of gemtuzumab ozogamicin in the development of hepatic veno-occlusive disease (VOD). Protocol Development
RT09-01 Primary graft failure following allogeneic hematopoietic cell transplant (HCT) for the treatment of hematological malignancies. Protocol Development
RT09-02 Effects of body mass in children with leukemias. Protocol Development
RT09-03 Comparison of clinical outcomes between myeloablative and RIC for haploidentical stem cell transplantation. Protocol Development
RT09-04/IB09-06s* Assessment of Genetic Polymorphisms and Transplant-Related Mortality in Relation to Conditioning Regimen before HLA-Matched Unrelated Donor Allogeneic HSCT. Protocol Development

Recently Published Studies

NumberTitleStatus
LE03-01 The effect of smoking on allogeneic transplant outcomes. Published

Publication(s)


Last updated: 06.4.2010